Endosane: International scientists team up with Sanity Group in a joint-venture aiming to develop a new generation of “game changing” psychiatric drugs with significantly reduced side effect profile
5. October 2021
Berlin, October 5th, 2021 – Sanity Group, a health and life-science company focused on natural compounds and cannabinoids, and an international team of scientists are now jointly developing pharmaceuticals for the treatment of neuropsychiatric and psychiatric disorders such as schizophrenia